Trial Profile
The purpose of this mono therapy study is to evaluate the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of BCD-145 (JSC BIOCAD, Russia) in patients with unresectable/metastatic melanoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Nurulimab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Biocad
- 15 Apr 2019 Status changed from recruiting to completed.
- 23 Mar 2018 New trial record